Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London Funding will enable new intranasal vaccine SynGEM® to be tested in phase I and IIa human clinical trial
Groningen, the Netherlands, January 20, 2016 – Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation and needle-free human vaccines for infectious diseases, today…